Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris

PHASE3

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Novartis has acquired the rights to ofatumumab and terminated the OPV116910 and OPV117059 studies. This decision is not linked to any safety consideration.

Conditions

Pemphigus

Interventions

DRUG: Ofatumumab
DRUG: Acetaminophen/paracetamol
DRUG: Antihistamine (cetirizine or equivalent)
DRUG: Prednisone/Prednisolone

Sponsor

GlaxoSmithKline